These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 22651108)
1. Sample size adaptation in fixed-dose combination drug trial. James Hung HM; Wang SJ J Biopharm Stat; 2012; 22(4):679-86. PubMed ID: 22651108 [TBL] [Abstract][Full Text] [Related]
2. Two-stage sample size re-estimation based on a nuisance parameter: a review. Proschan MA J Biopharm Stat; 2005; 15(4):559-74. PubMed ID: 16022163 [TBL] [Abstract][Full Text] [Related]
3. Adaptive statistical analysis following sample size modification based on interim review of effect size. Hung HM; Cui L; Wang SJ; Lawrence J J Biopharm Stat; 2005; 15(4):693-706. PubMed ID: 16022173 [TBL] [Abstract][Full Text] [Related]
4. Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis. Friede T; Kieser M Pharm Stat; 2011; 10(1):8-13. PubMed ID: 19943322 [TBL] [Abstract][Full Text] [Related]
6. Testing for the existence of a desirable dose combination. Hung HM; Chi GY; Lipicky RJ Biometrics; 1993 Mar; 49(1):85-94. PubMed ID: 8513112 [TBL] [Abstract][Full Text] [Related]
7. Bootstrap and second-order tests of risk difference. Lloyd CJ Biometrics; 2010 Sep; 66(3):975-82. PubMed ID: 19912176 [TBL] [Abstract][Full Text] [Related]
8. Optimal conditional error functions for the control of conditional power. Brannath W; Bauer P Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294 [TBL] [Abstract][Full Text] [Related]
10. On efficient two-stage adaptive designs for clinical trials with sample size adjustment. Liu Q; Li G; Anderson KM; Lim P J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105 [TBL] [Abstract][Full Text] [Related]
11. A free gift: an adaptive strategy in a single-arm trial using an exact test through the binomial distribution. Wang J J Biopharm Stat; 2012; 22(6):1127-36. PubMed ID: 23075012 [TBL] [Abstract][Full Text] [Related]
12. Increasing the sample size at interim for a two-sample experiment without Type I error inflation. Dunnigan K; King DW Pharm Stat; 2010; 9(4):280-7. PubMed ID: 19764040 [TBL] [Abstract][Full Text] [Related]
13. Internal pilots for observational studies. Gurka MJ; Coffey CS; Gurka KK Biom J; 2010 Oct; 52(5):590-603. PubMed ID: 20857422 [TBL] [Abstract][Full Text] [Related]
14. Sample size re-estimation in group-sequential response-adaptive clinical trials. Morgan CC Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942 [TBL] [Abstract][Full Text] [Related]
15. The reassessment of trial perspectives from interim data--a critical view. Bauer P; Koenig F Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517 [TBL] [Abstract][Full Text] [Related]
16. Comparison of maximum statistics for hypothesis testing when a nuisance parameter is present only under the alternative. Zheng G; Chen Z Biometrics; 2005 Mar; 61(1):254-8. PubMed ID: 15737101 [TBL] [Abstract][Full Text] [Related]
17. Increasing the sample size when the unblinded interim result is promising. Chen YH; DeMets DL; Lan KK Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876 [TBL] [Abstract][Full Text] [Related]
18. Two-stage tests for studying monotherapy and combination therapy in two-by-two factorial trials. Hung HM Stat Med; 1993 Apr; 12(7):645-60. PubMed ID: 8511441 [TBL] [Abstract][Full Text] [Related]
19. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials. Hung HM; Wang SJ; O'Neill R J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the statistical power for multiple tests: a case study. Yeo A; Qu Y Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]